CD28 superagonists: what makes the difference in humans?
In 2006, a clinical trial with the CD28 superagonistic antibody TGN1412 in London turned into a catastrophe. Studies are beginning to unravel the difference between the human and preclinical animal response to the antibody.
Schraven
Burkhart
B
Institute of Molecular and Clinical Immunology, Otto-von-Guericke-University Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany. burkhart.schraven@med.ovgu.de
Kalinke
Ulrich
U
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology*; D061067:Antibodies, Monoclonal, Humanized; D018106:CD28 Antigens / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D008213:Lymphocyte Activation; D008252:Macaca fascicularis; D008253:Macaca mulatta; D011961:Receptors, Fc / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction; D013045:Species Specificity; D013601:T-Lymphocytes / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018106:CD28 Antigens; D011961:Receptors, Fc; C509303:TGN-1412